2,697 followers
RT @gedefo_sefh: "phase 1 dose-escalation & expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor" https://…
RT @gedefo_sefh: "phase 1 dose-escalation & expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor" https://…
"phase 1 dose-escalation & expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor" https://t.co/Up5BFaEgxH
preliminary anti-tumor activity in biliary cancer-will be very interesting to see the results/mutational status of the expansion cohort. https://t.co/Xz3OHapoIw
Encouraging results from phase 1 dose-escalation & expansion study of binimetinib (MEK162) https://t.co/OnjiJRWL5L https://t.co/A1TN2Tvr3a